Press Release

ELC Group partners with mdi Europa GmbH to offer end-to-end regulatory solution for medical device companies in Europe

Preferred Partnership delivers complete consultancy support and expertise – from device registration to CE marking

Cambridge, UK, June 6 2012 – ELC GROUP, the pan-European pharmaceutical regulatory affairs organisation, today announces that it has formed a preferred European partner relationship with mdi Europa GmbH, a global regulatory consultancy for medical device and IVD companies. The two companies are partnering to provide a complete, end-to-end regulatory solution for medical device manufacturers in Europe – spanning initial device registration and documentation to CE marking and post-marketing services.

ELC Group has developed a strong track record and extensive expertise in medical device regulatory services, including regulation strategy, Medical Device Directive consultancy, device registration, and full technical file preparation. Through its Preferred Partnership arrangement with mdi Europa, ELC Group is now able to offer a one-stop, full-service consultancy solution to medical device manufacturers, focused on speeding time-to-market and easing the compliance process. With this new total service solution, ELC Group’s strengths in documentation support are complemented by mdi Europa’s skills in guiding companies to achieving CE certification and approvals, plus post-marketing device vigilance.

Commenting on today’s announcement, Marco Rubinstein, CEO of ELC Group said: “By joining hands with a regulatory organisation of the calibre of mdi Europa, we are offering our customers a true best-in-class solution for end-to-end medical device compliance. The breadth of this combined solution means that customers can benefit from a smoother regulatory process and faster time-to-market, all in the confidence that they are getting the very highest quality consultancy, support and advice available.”

mdi Europa Vice President Operations, Martina Sander-Giesemann, added: “It was most important for us to find a partner that has an equal understanding of customer service. With ELC Group, we have found an experienced, well-positioned partner that focuses on customer needs in the same way as we do. Regulatory compliance is often felt to be a burden – together with ELC Group, we do our utmost to take this burden off our mutual clients.”

ELC Group helps clients expedite time-to-market through a broad range of development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialisation services. ELC Group delivers its customised solutions through four core business segments: Regulatory Affairs Services; Medical Devices; EU REACH (Registration, Evaluation and Authorisation of Chemicals) Regulation Services; and Corporate Languages Solutions (Translations, Design, DTP, Localisation).

Press contacts
Akhil Jain
ELC Group
ajain [at] elc-group [dot] com
Phone: +420 22 491 00 00


Nicky Denovan
EvokedSet PR
nicky[at] evokedset [dot] com
Phone: +44 (0)7747 017654


About ELC Group

ELC GROUP is a leading global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries as well as REACH services to the Chemical industry. It helps companies that lack the resource (skills and knowledge) to cost effectively deliver regulatory affairs.

ELC Group provides full-service, multi-lingual consulting and cost-effective solutions to regulatory approvals using experts with in-depth knowledge and experience throughout the world. The team ranges from former FDA investigators to individuals with over 30 years of industry experience with broad capabilities. This includes integrated advanced technologies, regulatory affairs consulting and commercialisation services.

About mdi Europa GmbH

mdi Europa is a regulatory affairs consulting company specializing in CE-marking and regulatory affairs for both the medical and in vitro diagnostic medical device manufacturing industry. Its predominant role is that of “authorized representative”; a prerequisite for all non-European manufacturers without a subsidiary / place of business within the European Union. Services include labeling review, product registration, post market surveillance, product classification, vigilance, language requirements and general guidance in interpreting the Directives 90/385/EEC, 93/42/EEC & 98/79/EEC. For more information, visit www.mdi-europa.com


Please let us know any comments you have on this article:

Also see our

press coverage

News Index

05 Oct 2018

EU/US MRA - Brief overview and update

21 Aug 2018

Brexit - has the music stopped?

13 Jul 2018

Recent EMA Brexit Survey

15 Jun 2018

The EMA: 100 not out

08 May 2018

MHRA sets its post-Brexit strategic direction

12 Apr 2018

Brexit - Stick or Twist?

20 Mar 2018

Clinical Trials: all change 2019

22 Jan 2018

Orphan Medicines: almost 20 years on

15 Dec 2017

Update on Brexit developments

05 Oct 2017

How recent moves by the FDA spell good news for generics in the US

11 Sep 2017

Medicines for the Elderly – is your drug development strategy up to the mark?

14 Aug 2017

The MNAT initiative – what’s new?

19 Jul 2017

ICH Q12: Light at the end of the tunnel…?

05 Jun 2017

Q3D: Are your established products in compliance?

02 Jun 2017

Key pharmacovigilance trends to watch

08 May 2017

EMA updates guidance on PSURs

10 Apr 2017

New EMA Consultation on the Quality of Inhaled Pharmaceutical Products

16 Mar 2017

European Parliament’s adoption of ‘Options for improving access to medicines’ procedure

16 Feb 2017

Article 58: a hidden potential

24 Jan 2017

Global lifesciences partner ELC Group teams with PSR Group for advanced drug development

19 Jan 2017

A positive step forward for Biosimilar registration

20 Dec 2016

Falsified Medicines Directive – Are you making the right preparations?

21 Nov 2016

New Public consultation launched by the European Commission (EC)

19 Oct 2016

Transatlantic collaboration to boost research and development of medicines for rare diseases

03 Jun 2016

ELC Group to showcase regulatory affairs solutions at CPhI events in Shanghai and Barcelona

16 Jun 2015

ELC Group in early-stage development of novel influenza vaccine

09 Jun 2015

ELC Group expands into pharmaceutical product development market

21 Apr 2015

ELC Group signs 1.5 million Euro regulatory affairs contract with Chinese pharma giant

24 Feb 2015

Fast-growing regulatory affairs service provider ELC Group expands corporate presence in Czech Republic

02 Feb 2015

ELC GROUP to present at “Regulatory & Legal Affairs in Russia 2015” Conference

15 Sep 2014

Pharma eReport delivers V5-compliant solution to help MAHs meet December 31st XEVMPD resubmission deadline

20 Aug 2014

ELC Group Appoints Dr. Siddharth Chachad as Head of Global Clinical Development and Medical Affairs

28 Jul 2014

ELC Group Appoints Head of Regulatory Affairs for Russia and CIS

14 Apr 2014

Global regulatory affairs specialist ELC Group appoints Localization Business Development Manager for new US Office

10 Oct 2013

Global regulatory affairs specialist ELC Group accelerates international expansion plans following 25% revenue growth in 2013

17 Sep 2013

Global regulatory affairs specialist ELC Group appoints former MHRA Expert Medical Assessor

23 Apr 2013

Global regulatory affairs specialist ELC Group receives accreditation to provide readability testing in Romania

27 Feb 2013

Global regulatory affairs specialist ELC Group to deliver pharmaceutical training event in Latvia

20 Feb 2013

Global pharmaceutical regulatory affairs specialist ELC Group launches Clinical Trials services

10 Jan 2013

Global pharmaceutical regulatory affairs specialist ELC Group hosts International Training Seminar in Mumbai, India

31 Dec 2012

2012 Events

07 Nov 2012

Global pharmaceutical regulatory affairs specialist ELC Group establishes new office in Singapore

22 Aug 2012

Global pharmaceutical regulatory affairs specialist ELC Group increases operational support in Ahmedabad

12 Jun 2012

XEVMPD software provider Pharma eReport launches Excel Data Import Service

06 Jun 2012

ELC Group partners with mdi Europa GmbH to offer end-to-end regulatory solution for medical device companies in Europe

28 Mar 2012

ELC Group joins DIA EuroMeeting in Copenhagen

21 Mar 2012

EVMPD software provider Pharma eReport announces full general availability of Centrality XEVMPD compliance solution

08 Mar 2012

ELC Group Hosts Successful International Regulatory Seminar

06 Mar 2012

Pharmaceutical regulatory affairs specialist ELC Group opens new office in Mumbai

23 Feb 2012

Regulatory challenges for 2012 and their impact on marketing authorisation

21 Feb 2012

ELC Group launches new software subsidiary Pharma eReport to provide complete EVMPD compliance solution

08 Feb 2012

Pharmaceutical regulatory affairs specialist ELC Group establishes global HQ in Cambridge, UK

07 Dec 2011

Past president of TOPRA and ELC GROUP Advisor speaks at International Regulatory Seminar in Ahmedabad 23 February 2012

27 Sep 2011

ELC GROUP Advisory Board’s Dr. Paolo Biffignandi to write opinion column for industry leading publication

12 Jul 2011

ELC Group aim to foster strategic and economic ties within India and China

25 May 2011

ELC Group announces doubled revenues

11 May 2011

ELC Group appoints former TOPRA President